227 related articles for article (PubMed ID: 27401345)
1. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition.
Sashida G; Wang C; Tomioka T; Oshima M; Aoyama K; Kanai A; Mochizuki-Kashio M; Harada H; Shimoda K; Iwama A
J Exp Med; 2016 Jul; 213(8):1459-77. PubMed ID: 27401345
[TBL] [Abstract][Full Text] [Related]
2. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
[TBL] [Abstract][Full Text] [Related]
3. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
4. Hmga2 collaborates with
Ueda K; Ikeda K; Ikezoe T; Harada-Shirado K; Ogawa K; Hashimoto Y; Sano T; Ohkawara H; Kimura S; Shichishima-Nakamura A; Nakamura Y; Shikama Y; Mori T; Mason PJ; Bessler M; Morishita S; Komatsu N; Shide K; Shimoda K; Koide S; Aoyama K; Oshima M; Iwama A; Takeishi Y
Blood Adv; 2017 Jun; 1(15):1001-1015. PubMed ID: 29296743
[TBL] [Abstract][Full Text] [Related]
5. [The role of HMGA2 in myeloproliferative neoplasms].
Ikeda K
Rinsho Ketsueki; 2018; 59(10):2067-2074. PubMed ID: 30305510
[TBL] [Abstract][Full Text] [Related]
6. Hmga2 promotes the development of myelofibrosis in Jak2
Dutta A; Hutchison RE; Mohi G
Blood; 2017 Aug; 130(7):920-932. PubMed ID: 28637665
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis.
Fan N; Tang Y; Wu Z; Guan M; Chen B; Xu X; Ma W; Xu X; Zhang X
Ann Hematol; 2018 Jul; 97(7):1193-1208. PubMed ID: 29560522
[TBL] [Abstract][Full Text] [Related]
8. [Pathogenic role of insufficiency of polycomb repressive complex in primary myelofibrosis].
Shinoda D
Rinsho Ketsueki; 2023; 64(9):998-1006. PubMed ID: 37793876
[TBL] [Abstract][Full Text] [Related]
9. EZH2 mutational status predicts poor survival in myelofibrosis.
Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM
Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040
[TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
11. Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.
Wang C; Oshima M; Sato D; Matsui H; Kubota S; Aoyama K; Nakajima-Takagi Y; Koide S; Matsubayashi J; Mochizuki-Kashio M; Nakano-Yokomizo T; Bai J; Nagao T; Kanai A; Iwama A; Sashida G
J Clin Invest; 2018 Aug; 128(9):3872-3886. PubMed ID: 30080177
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.
Sahasrabuddhe AA; Chen X; Chung F; Velusamy T; Lim MS; Elenitoba-Johnson KS
Oncogene; 2015 Jan; 34(4):445-54. PubMed ID: 24469040
[TBL] [Abstract][Full Text] [Related]
13. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes.
Oguro H; Yuan J; Tanaka S; Miyagi S; Mochizuki-Kashio M; Ichikawa H; Yamazaki S; Koseki H; Nakauchi H; Iwama A
J Exp Med; 2012 Mar; 209(3):445-54. PubMed ID: 22351929
[TBL] [Abstract][Full Text] [Related]
14. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
[TBL] [Abstract][Full Text] [Related]
15. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
[TBL] [Abstract][Full Text] [Related]
16. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
17. JAK2V617F influences epigenomic changes in myeloproliferative neoplasms.
Chen CC; Chiu CC; Lee KD; Hsu CC; Chen HC; Huang TH; Hsiao SH; Leu YW
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):470-476. PubMed ID: 29066347
[TBL] [Abstract][Full Text] [Related]
18. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
19. Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells.
Koppens MA; Bounova G; Gargiulo G; Tanger E; Janssen H; Cornelissen-Steijger P; Blom M; Song JY; Wessels LF; van Lohuizen M
Gastroenterology; 2016 Oct; 151(4):684-697.e12. PubMed ID: 27342214
[TBL] [Abstract][Full Text] [Related]
20. Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis.
Shinoda D; Nakajima-Takagi Y; Oshima M; Koide S; Aoyama K; Saraya A; Harada H; Rahmutulla B; Kaneda A; Yamaguchi K; Furukawa Y; Koseki H; Shimoda K; Tanaka T; Sashida G; Iwama A
Leukemia; 2022 Feb; 36(2):452-463. PubMed ID: 34497325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
